Key facts
- Qitan Tech’s last known valuation is $690.2M (Dec 2022).
- It has raised $198.9M; the latest was Later Stage VC in Dec 2025.
- Notable investors include GL Ventures, CDH Investments, Baidu Ventures, Orinno Capital, Yinxinggu Capital — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Qitan Tech
- ·The full record, as it builds
Funding rounds
No funding rounds for Qitan Tech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Qitan Tech
Manufacturer of nanopore sequencing systems designed to enable real-time genetic analysis and molecular research. The company offers nanopore sequencers, portable and desktop platforms, flow cells, reagents, and sequencing software with long-read and real-time capabilities, enabling research institutions and medical laboratories to conduct efficient genomic analysis and accelerate biological research.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2016
- Employees
- 270
- Website
- qitantech.com/
- Ownership
- Privately Held (backing)
Qitan Tech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qitan Tech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qitan Tech in its N-PORT filings yet. We sweep new filings monthly.